Viatris
VTRS • NASDAQ
Viatris is a drug manufacturers - specialty & generic company in the healthcare sector trading on NASDAQ, led by CEO Scott Andrew Smith, with a market cap of $15.0B.
CEOScott Andrew Smith
Next Earnings
Upcoming earnings announcement for Viatris
Date
Thursday, May 7, 2026 (in a month)
Timing
Before Market Open (6:00 AM New York)
Fiscal Period
Q1 2026
EPS Estimate
$0.50
Revenue Estimate
$3.4B
Earnings History
Past 12 earnings reports for Viatris
| Date | Period | EPS | EPS Surprise | Revenue | Rev. Surprise | Filing |
|---|---|---|---|---|---|---|
| Feb 26, 2026 | Q4 2025 | $0.57Est: $0.53 | +7.5% | $3.7BEst: $3.5B | +4.7% |  10-K |
| Nov 6, 2025 | Q3 2025 | $0.67Est: $0.62 | +8.1% | $3.8BEst: $3.6B | +3.8% | 10-Q |
| Aug 7, 2025 | Q2 2025 | $0.62Est: $0.56 | +10.7% | $3.6BEst: $3.5B | +3.1% | 10-Q |
| May 8, 2025 | Q1 2025 | $0.50Est: $0.51 | -2.0% | $3.3BEst: $3.3B | -1.4% | 10-Q |
| Feb 27, 2025 | Q4 2024 | $0.54Est: $0.57 | -5.3% | $3.5BEst: $3.6B | -2.6% | 10-K |
| Nov 7, 2024 | Q3 2024 | $0.75Est: $0.68 | +10.3% | $3.8BEst: $3.7B | +1.1% | 10-Q |
| Aug 8, 2024 | Q2 2024 | $0.69Est: $0.68 | +1.5% | $3.8BEst: $3.8B | +0.4% | 10-Q |
| May 9, 2024 | Q1 2024 | $0.67Est: $0.67 | 0.0% | $3.7BEst: $3.7B | -1.0% | 10-Q |
| Feb 28, 2024 | Q4 2023 | $0.62Est: $0.65 | -4.6% | $3.8BEst: $3.9B | -1.1% | 10-K/A |
| Nov 7, 2023 | Q3 2023 | $0.79Est: $0.74 | +6.8% | $3.9BEst: $4.0B | -1.9% | — |
| Aug 7, 2023 | Q2 2023 | $0.75Est: $0.71 | +5.9% | $3.9BEst: $3.9B | +0.6% | — |
| May 8, 2023 | Q1 2023 | $0.77Est: $0.69 | +11.6% | $3.7BEst: $3.8B | -2.1% | — |